122 research outputs found
VALUE OF SIMULTANEOUS MONITORING OF RIGHT-VENTRICULAR OXYGEN-SATURATION AND PRESSURE USING BIOSENSORS
Value of digoxin in heart failure and sinus rhythm: New features of an old drug?
Digoxin has been a controversial drug since its introduction >200 years ago. Although its efficacy in patients with heart failure and atrial fibrillation is clear, its value in patients with heart failure and sinus rhythm has often been questioned. In the 1980s, reports of some large-scale trials indicated that digoxin, with or without vasodilators or angiotensin-converting enzyme inhibitors, reduced signs and symptoms of congestive heart failure and improved exercise tolerance. This beneficial influence was mainly found in patients with more advanced heart failure and dilated ventricles, whereas the effect in those with mild disease appeared to be less pronounced. In the last few years, new data have shown that digoxin may also have clinical value in mild heart failure, either when used in combination with other drugs or when administered alone. As neurohumoral activation has increasingly been recognized to be a contributing factor in the disease progression of chronic heart failure, the modulating effects of digoxin on neurohumoral and autonomic status have received more attention. Also, there is evidence that relatively low doses of digoxin may be at least as effective as higher doses and have a lower incidence of side effects. Further, the recognition that the use of digoxin too early after myocardial infarction may be harmful and the development of other drugs, in particular angiotensin-converting enzyme inhibitors, have obviously changed the place of digoxin in the treatment of chronic heart failure. The large-scale survival trial by the Digitalis Investigators Group (DIG), whose preliminary results have recently been presented, has shown that although digoxin has a neutral effect on total mortality during long-term treatment, it reduces the number of hospital admissions and deaths due to worsening heart failure. The potentially new features of the old drug digoxin are discussed in this review
NEW DOPAMINE AGONISTS IN CARDIOVASCULAR THERAPY
Dopamine, a naturally occurring catecholamine, has been extensively used in intensive care for many years. Dopamine stimulates different types of adrenergic receptors: alpha-1 and -2, beta-1 and -2, and dopamine-1 and -2. The renal effects of dopamine are the result of dopamine-1 receptor (DA1) stimulation: renal vasodilation and natriuresis. DA2-receptor stimulation lowers plasma aldosterone and norepinephrine levels. Recently, several new dopamine agonists have been developed. Fenoldopam, a selective DA1-agonist, induces renal and systemic vasodilation with an increase in renal blood flow. This is accompanied by an increase in natriuresis and diuresis. Dopexamine, a DA1- and beta-2 agonist, is administered intravenously. It is used, like dopamine, in the treatment of congestive heart failure. However, the use of dopamine (and dopexamine) is limited by its unique intravenous availability. Ibopamine is an aselective dopamine agonist for oral use. Several clinical studies have demonstrated the efficacy of ibopamine in the treatment of patients with congestive heart failure and its mild renal effects
- …